DVAX — Dynavax Technologies Share News
0.000.00%
Last trade - 00:00- $1.76bn
- $1.38bn
- $277.25m
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
OneSpaWorld jumps as co poised to join S&P SmallCap index
Sanofi targets high single digit sales growth in 2026, plans share buyback (updated)
Focus: Vaccine makers feel a chill as US Health Secretary Kennedy's rhetoric becomes reality
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Snowflake, Hecla Mining, Newmont
U.S. STOCKS ON THE MOVE-Vertex, Nike, Intel
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Vertex, Nike, Intel
U.S. STOCKS ON THE MOVE-premarket
Deals of the day-Mergers and acquisitions
Dynavax soars as French drug maker Sanofi to acquire co
Sanofi to acquire hepatitis B vaccine maker Dynavax for $2.2 billion (updated)
Sanofi to acquire US biotech Dynavax for $2.2 billion
Live Markets: Before the bell: festive trading, but M&A keeps going
Brief: Dynavax Presents Positive Topline Data From Part 1 Of Phase 1/2 Trial For Shingles Vaccine Candidate At Idweek 2025 And Announces Initiation Of Part 2 Of Trial
U.S. STOCKS ON THE MOVE-Energy Fuels, Dynavax Technologies, Oklo
U.S. STOCKS ON THE MOVE-Yatsen, International Paper, GE Vernova
Dynavax's shingles vaccine shows similar immune response to GSK's shot in study (updated)